Base to Base Biotech

This week, our subjects are a silica nanoparticle gene delivery system in a conversation with Nigel Theobald, CEO of N4 Pharma, and a point-of-care diagnostics system for urinary tract infections developed by Welsh company Llusern Scientific. We spoke with the company's co-founder and CEO, Dr Emma Hayhurst. Interview times: 03:00 N4 Pharma 24:45 Llusern Scientific N4 Pharma N4 Pharma is a UK biote...

This week, we have conversations with Sean MacDonald, CEO of Domain Therapeutics, Carina Kern, CEO and founder of LinkGevity, and Nadia Harhen, general manager of AI Simulation at SandboxAQ. Interview times: 03:41 Domain Therapeutics 27:14 SandboxAQ 48:04 LinkGevity Domain Therapeutics Domain Therapeutics is delivering breakthrough GPCR-targeting therapies in immuno-oncology and inflammation. Doma...

This week, we have conversations with Phil L'Huillier, CEO of Scancell, and Shai Melcer, head of Israel’s National Bio-Convergence Program. Interview times: 03:25 Scancell 28:04 National Bio-Convergence Program Scancell Scancell recently announced a partnership with the UK’s NHS Cancer Vaccine Launch Pad, enabling fast-tracked access for melanoma patients. The company’s DNA off-the-shelf cancer va...

This week, we have conversations with Peter Nolan, CEO of BlackFinBio, and Kim Kraemer, CEO and founder of Waterhouse Brands. Interview times: 01:57 BlackFinBio 19:36 Waterhouse Brands BlackFinBio BlackfinBio is a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases. Its pipeline comprises BFB-101, a clinical stage AP4B1 replacement adeno-asso...

This week, we have conversations with Dr Peter Tummino, president of R&D at Nimbus, and Alex Del Priore, senior vice president, manufacturing at Syngene International Limited. Interview times: 02:00 Syngene 20:27 Nimbus Therapeutics Nimbus Therapeutics Nimbus Therapeutics is perhaps best known for two high-profile deals – Gilead’s $1.2bn acquisition of its NASH program and Takeda’s $4bn acquis...

This week, our guests are Ben Cliff, CEO of UK-based CRO, Concept Life Sciences, and Ravi Rao, chief medical officer of Sitryx. Interview times 01:12 Sitryx 19:40 CLS Concept Life Sciences Concept Life Sciences (CLS), a provider of drug discovery, development, and manufacturing services to the global pharma and biotech sector, recently announced an investment into its drug discovery capabilities....

This week, we have a conversation with Ben Zeskind, CEO and co-founder of Immuneering, and a discussion with Tasso Inc.’s co-founder and chief technology officer, Erwin Berthier. Interview times: 01:27 Tasso 27:25 Immuneering Immuneering There is no cure for HIV, yet many people with the virus now live long, healthy lives – thanks to available medicines that prevent disease progression with minima...

This week, we have a conversation with Vidmantas Šakalys, CEO of bioprinting company Vital3D Technologies, and a chat with Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx, another of the companies that attended the American Association for Cancer Research (AACR) annual meeting in Chicago recently. Interview times: 01:47 Vital3D Technologies 20:46 AOA Dx Vital3D Technologies Lithuanian company Vi...

This week, we’re talking to some of the companies that attended the American Association for Cancer Research (AACR) annual meeting in Chicago. We have interviews with Microbiotica, 1Cell. Ai, and Tessellate Bio. Interview times: 01:55 Tessellate Bio 17:02 1Cell. Ai (formerlyOneCell Diagnostics) 44:04 Microbiotica Microbiotica Mat Robinson, SVP Research at Microbiotica , is one of our guests. Micro...

This week on the podcast, we have a conversation with Elise de Reus, the co-founder of Cradle, a biotech startup that is revolutionising protein design, and a chat about improving hospital operations with Proximie’s CEO and founder, plastic surgeon Dr. Nadine Hachach-Haram. Interview times: 01:55 Proximie 21:40 Cradle Proximie Proximie has built the only cloud OS for intelligent operating rooms. W...

This week on the podcast, we have a conversation with Tim Tinnel, executive vice president/chief operating officer of Intelliguard, talking about – among other things – the looming Drug Supply Chain Security Act (DSCSA) deadline, and Jorge Jorge Santos da Silva, founder and CEO of MoonLake Immunotherapeutics, about its Nanobody programme. Interview times: 01:42 MoonLake Immunotherapeutics 25:24 In...

This week on the podcast, we have a conversation with Steve Ruston, CEO of Persica Pharmaceuticals, about treating chronic low back pain, and with Monika Paulė, CEO and co-founder of Caszyme. Interview time stamps: Times: 01:40 Caszyme 16:04 Persica Pharmaceuticals Persica Pharmaceuticals Persica is developing a potentially transformative non-opioid treatment for chronic low back pain (cLBP) with...

This week on the podcast, we have a conversation with Vitalant’s Kevin Land, executive medical director, Biotherapies, and VP of Clinical Services, and Becky Cap, SVP, Biotherapies; and chat with Brainomix CEO and co-founder Michalis Papadakis about making a difference in getting faster treatments for stroke victims. Times: 01:52 Brainomix 21:44 Vitalant Vitalant Vitalant , which used to be known...

This week on the podcast, we have conversations about hiring in the lifesciences industry in 2025, and about a potential new class of synthetic therapeutics. Interview times: 02:49 ThirdLaw Molecular 21:14 Occam Global ThirdLaw Molecular ThirdLaw Molecular is a biotech company that has pioneered the discovery and development of Spiroligomer molecules – a groundbreaking new platform for targeted dr...

Interview timestamps: 02:20 Satellos 26:00 EVŌQ Nano Antibiotic-resistant infections are a top 10 global health threat demanding urgent innovation. A US-based nanotech company, EVŌQ Nano , has developed a novel nanoparticle that destroys bacteria from the inside – without triggering antimicrobial resistance (AMR). The nanoparticle is already in development for an inhaled therapeutic for Cystic Fib...

Our guest, Dr. Hernan Bazan, is the CEO and co-founder of South Rampart Pharma . He is also a board-certified vascular surgeon. Bazan is also the recipient of the 2024 NIH HEAL (Helping to End Addiction Long-term) Director's Trailblazer Award for his work in developing a non-addictive pain medication as an alternative to opioids. At South Rampart Pharma, he is leading the development of SRP-001, a...

Osteoboost Health Inc. just announced its sixth U.S. patent for its wearable device that uses vibration therapy to strengthen bones and help women live stronger, longer lives. The company is tackling acritical health challenge: osteopenia, a condition affecting millions of women worldwide. Osteoboost is the first and only FDA-cleared, non-drug prescription treatment for low bone density. Powered b...